Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17025650 | 0.84 | CYP17A1 (0.41) | MLYCDCYP17A1POLBALDH1A1HDAC1 | |
| SCHEMBL25043894 | 0.84 | CYP17A1 (0.54) | MLYCDCYP17A1LMNACYP1A2CYP3A4 | |
| SCHEMBL10318265 | 0.82 | ALDH1A1 (0.50) | NPSR1LMNAPOLBGAAALDH1A1 | |
| SCHEMBL2283371 | 0.81 | PPARG (0.51) | LMNAGAAMAPK1ALDH1A1HDAC1 | |
| SCHEMBL9104625 | 0.81 | CA12 (0.44) | CYP17A1NPSR1LMNACYP1A2POLB | |
| SCHEMBL8739566 | 0.80 | CYP17A1 (0.49) | MLYCDCYP17A1CA12CA1CA9 | |
| SCHEMBL11982645 | 0.79 | HDAC1 (0.46) | HDAC1HDAC8HDAC6LCK | |
| SCHEMBL29626601 | 0.79 | ATR (0.43) | MLYCDCYP17A1 | |
| SCHEMBL6180657 | 0.79 | ATR (0.43) | MLYCDCYP17A1 | |
| SCHEMBL8739191 | 0.79 | CYP17A1 (0.44) | MLYCDCYP17A1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563558-B2 | Substituted pyridine urea compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2012078673-A1 | SUBSTITUTED PYRIDINE UREA COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142708-A1 | SUBSTITUTED PYRIDINE UREA COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142708-A1 | SUBSTITUTED PYRIDINE UREA COMPOUNDS | MAPK1, MAP3K1, MAP3K8 | MLYCD 3932/4885CYP17A1 3235/4885NPSR1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.